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ABSTRACT
Background
Recent outbreaks of highly pathogenic influenza A H5N1 viruses in humans and avian species
that began in Asia and have spread to other continents underscore an urgent need to develop
vaccines that would protect the human population in the event of a pandemic.
Methods and Findings
Live, attenuated candidate vaccines possessing genes encoding a modified H5 hemag-
glutinin (HA) and a wild-type (wt) N1 neuraminidase from influenza A H5N1 viruses isolated in
Hong Kong and Vietnam in 1997, 2003, and 2004, and remaining gene segments derived from
the cold-adapted (ca) influenza A vaccine donor strain, influenza A/Ann Arbor/6/60 ca (H2N2),
were generated by reverse genetics. The H5N1 ca vaccine viruses required trypsin for efficient
growth in vitro, as predicted by the modification engineered in the gene encoding the HA, and
possessed the temperature-sensitive and attenuation phenotypes specified by the internal
protein genes of the ca vaccine donor strain. More importantly, the candidate vaccines were
immunogenic in mice. Four weeks after receiving a single dose of 10
6 50% tissue culture
infectious doses of intranasally administered vaccines, mice were fully protected from lethality
following challenge with homologous and antigenically distinct heterologous wt H5N1 viruses
from different genetic sublineages (clades 1, 2, and 3) that were isolated in Asia between 1997
and 2005. Four weeks after receiving two doses of the vaccines, mice and ferrets were fully
protected against pulmonary replication of homologous and heterologous wt H5N1 viruses.
Conclusions
The promising findings in these preclinical studies of safety, immunogenicity, and efficacy of
the H5N1 ca vaccines against antigenically diverse H5N1 vaccines provide support for their
careful evaluation in Phase 1 clinical trials in humans.
The Editors’ Summary of this article follows the references.
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On several occasions since 1997, outbreaks of highly
pathogenic avian inﬂuenza (HPAI) H5N1 infections have
occurred in poultry and in humans, fueling public health
concerns over their potential to ignite a pandemic that would
cause signiﬁcant morbidity and loss of life. The most recent
H5N1 outbreak in poultry, which began in late 2003, affected
at least ten Asian countries initially, but recent reports
indicate that H5N1 viruses have been isolated in wild birds
and poultry in several countries in Asia, Europe, and Africa.
More importantly, human cases of H5N1 infections have been
reported since December 2003 in nine countries, with a total
of 194 laboratory-conﬁrmed cases and 109 fatalities as of 12
April 2006 (http://www.who.int/csr/disease/avian_inﬂuenza/
country/cases_table_2006_04_12/en/). Although antiviral
drugs are valuable for the prevention and treatment of H5N1
infections, they are limited in supply; in addition, resistance
to these antivirals—which include drugs that target neura-
minidase (NA) as well as those that block M2 ion channel
function—has been described in multiple isolates [1–3]. The
development of an H5N1 vaccine is recognized as the primary
strategy to protect humans against a possible H5N1 pan-
demic. Infections with H5N1 inﬂuenza viruses in avian
species and in humans have been occurring sporadically
since 1997 and phylogenetic and antigenic analyses of H5N1
viruses collected over this period indicate that they have
evolved into different sublineages or clades: 2004 viruses are
designated clade 1, 2003 viruses clade 19, some 2005 isolates
c l a d e2 ,a n dt h e1 9 9 7v i r u s e sc l a d e3[ 4 , 5 ] .A n t i g e n i c
differences among inﬂuenza viruses are usually identiﬁed by
analysis of speciﬁc postinfection ferret antisera in reciprocal
hemagglutination-inhibition (HAI) assays. Reports of genetic
and antigenic changes observed in the H5N1 viruses isolated
between 1997 and 2005 have raised concern about the ability
of a vaccine generated from a single selected strain to protect
against a diverse set of viruses [5,6].
The two modalities that are licensed as vaccines in the U.S.
against human inﬂuenza viruses are inactivated split virus
and live, attenuated virus vaccines. The development of
effective vaccines against HPAI H5N1 viruses, however,
presents several challenges. Due to their high pathogenicity,
handling of the wild-type (wt) viruses requires biosafety level 3
(BSL-3) containment. Moreover, these viruses are highly
pathogenic in chickens and are also lethal for chick embryos,
so they cannot be propagated efﬁciently and safely in eggs.
Several strategies have been explored in attempts to over-
come these obstacles. These include the use of a low-
pathogenicity H5N3 avian inﬂuenza virus that is antigenically
related to circulating strains [7], the use of recombinant H5
hemagglutinin (HA) expressed in baculovirus [8], the use of
recombinant adenoviruses expressing the H5 HA [9,10], and
the production of attenuated seed viruses with the H5 HA
modiﬁed by means of reverse genetics [11,12].
Nicholson and colleagues [7] investigated the feasibility of
using an antigenically related, low-pathogenicity H5N3
inﬂuenza virus (inﬂuenza A/duck/Singapore/97) inactivated
virus vaccine to protect against HPAI H5N1. The vaccine was
safe and well tolerated but was immunogenic only when
administered with the adjuvant MF59. Putative protective
antibody levels were not detectable in study participants 16
mo after receiving two doses [13], but signiﬁcant boosting of
antibody responses was seen upon administration of a third
dose of vaccine. Although the geometric mean titers were low
in all participants, higher seroconversion rates and cross-
reactive antibodies were seen among participants who
received the adjuvanted vaccine [14]. These studies demon-
strated that an inactivated virus vaccine against H5N1
inﬂuenza viruses generated from antigenically related, low-
pathogenicity avian viruses is weakly immunogenic but it can
induce broadly reactive antibodies when administered in
multiple doses with adjuvant [7,13,14].
A baculovirus-expressed recombinant H5 protein vaccine
was evaluated in Phase 1 clinical studies in humans [8]. The
vaccine was well tolerated but was poorly immunogenic; only
52% of participants who received two doses of 90 lgo f
vaccine developed a neutralizing antibody response to the
vaccine.
Two adenoviral vectors expressing full-length H5 HA were
tested in mice and poultry and, after two doses, were found to
be immunogenic and protective against challenge with
homologous and heterologous H5N1 wt inﬂuenza viruses
[9,10]. These vaccine candidates elicited both humoral and
cellular immune responses, and the protection against
heterologous challenge was presumed to be mediated by the
cellular immune response.
Multiple basic amino acid residues adjacent to the HA1-
HA2 proteolytic cleavage site of HA of HPAI H5 and H7
viruses constitute a virulence motif that makes the HA
cleavable by intracellular and extracellular proteases, thereby
altering virus tropism and its ability to spread systemically
(reviewed in [48]). Several investigators have developed
experimental H5N1 inﬂuenza vaccines in which the HA
cleavage site sequence is modiﬁed, resulting in the generation
of a low-pathogenicity seed virus that can be handled under
standard BSL-2 laboratory containment used for the pro-
duction of current interpandemic human inﬂuenza vaccines
[11,12]. Li and colleagues [15] reported the generation of two
live, attenuated, ca, temperature-sensitive (ts) vaccine viruses
based on two 1997 human H5N1 inﬂuenza isolates. The
vaccine viruses were immunogenic in ferrets and retained the
antigenicity of the wt parental viruses, demonstrating that
production of live, attenuated recombinant H5 viruses
containing a modiﬁed HA and the A/Ann Arbor/6/60 ca (AA
ca) internal protein genes is a useful approach to the
generation of vaccines against HPAI viruses. However, these
vaccines were not tested in mice or humans. Subbarao and
colleagues [11] reported the use of the same general approach
to produce an inactivated experimental H5N1 inﬂuenza
vaccine based on a 1997 H5N1 virus. The seed virus was
generated by reverse genetics in 293T cells, a substrate that is
not acceptable for use in human vaccines. Subsequently,
Webby and colleagues [12] generated a recombinant H5N1
inﬂuenza virus in Vero cells, in which the modiﬁed HA and
NA genes were derived from A/Hong Kong/213/2003 (H5N1)
and the internal protein genes were derived from A/Puerto
Rico/8/34 (H1N1). This vaccine was immunogenic in mice
when administered with incomplete Freund’s adjuvant and
provided a dose-dependent protection against heterologous
wt H5N1 viruses [16]. A similarly generated inactivated
subvirion vaccine, based on A/Vietnam/1203/2004 (H5N1)
has been evaluated in Phase 1 studies in healthy adult
volunteers [17]. Although a correlation was observed between
the dose of vaccine and immunogenicity, the vaccine was
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immunized with two 90 lg doses of the vaccine developed
antibody responses that had been predicted to be protective
in two assays. The vaccine is now being evaluated in children
and in the elderly. Evaluation of strategies to improve
immunogenicity of the inactivated subvirion vaccine with
adjuvants and dose-sparing regimens such as intradermal
delivery, are ongoing. Thus, to date, the immunogenicity of
inactivated virus vaccines that were evaluated in clinical trials
is suboptimal and require at least two doses and/or the use of
adjuvants.
We have been developing live, attenuated inﬂuenza virus
vaccines because they have properties that make them
attractive vaccines for the prevention of pandemic inﬂuenza
in humans, including (1) stimulation of an immune response
in inﬂuenza A virus-naı ¨ve individuals following a single dose
of vaccine; (2) safety for fully susceptible seronegative
individuals; (3) induction of cross-reactive immune responses;
(4) poor transmissibility; and (5) genetic and phenotypic
stability [18,19,20,21]. In the present study, three candidate
live, attenuated H5N1 vaccine viruses were generated follow-
ing rescue in Vero cells. Each of these vaccines, produced in
eggs, contains a different H5 HA (from 1997, 2003, and 2004
H5N1 viruses) with the multibasic motif deleted, an accom-
panying avian N1 NA, and the set of six internal protein
genes of the master donor virus AA ca. The three H5N1 ca
viruses bear the phenotypes predicted by the modiﬁcation
engineered in the HA gene (trypsin dependence) and those
speciﬁed by the internal protein genes of the AA ca virus (ts
and attenuation [att]). The candidate H5N1 ca vaccine viruses
were evaluated for immunogenicity in mice and for efﬁcacy
in mice and ferrets. The breadth of immunity that could be
induced by immunization with live, attenuated H5N1
vaccines was determined in cross-protection studies using
genetically and antigenically diverse H5N1 viruses isolated
over an eight-year period representing different clades for
challenge.
Methods
Viruses
The H5 HA and N1 NA of the reassortant H5N1 2003 and
2004 ca vaccine viruses were derived from inﬂuenza A/HK/213/
2003 (H5N1 2003 wt) and A/VN/1203/2004 (H5N1 2004 wt)
viruses,respectively, andtheinternal proteingenescamefrom
the AA ca donor virus. The H5N1 1997 reassortant vaccine
candidate’s H5 HA was derived from A/HK/491/1997 (H5N1
1997 wt), its N1 NA from A/HK/486/1997 (H5N1), and the
remaining gene segments from AA ca. A/Beijing/262/95 ca
(H1N1), which was generated by MedImmune Vaccines for
seasonal inﬂuenza, was used as a control in evaluating the
neurotropism of the viruses. A/New Caledonia/99 ca (H1N1)
was generated by MedImmune Vaccines and was used as a
controlfor evaluatingvaccine efﬁcacy inferrets.A/Ann Arbor/
6/60 (H2N2) wt (AA wt) and AA ca viruses were obtained from
MedImmune Vaccines. Additional inﬂuenza A viruses used for
challenge studies were A/Vietnam/JPHN30321/2005 (H5N1),
which belongs to clade 1 [4], and A/Indonesia/05/2005 (H5N1),
which belongs to clade 2 (R. Donis, Inﬂuenza Branch, Centers
for Disease Control and Prevention, Atlanta, Georgia, United
States, personal communication). The wt H5N1 viruses used in
this study were kindly provided by N. Cox and A. Klimov,
InﬂuenzaBranch,CentersforDiseaseControlandPrevention.
Virus stocks for the wt viruses were propagated in the
allantoic cavity of 9- to 11-day-old embryonated speciﬁc
pathogen-free (SPF) hen’s eggs at 37 8C. The allantoic ﬂuids
from eggs inoculated with wt viruses were harvested 24 h
postinoculation and tested for hemagglutinating activity.
Eggs inoculated with ca reassortant viruses were incubated at
33 8C and were harvested 3 d postinoculation. Infectious
allantoic ﬂuids were pooled, divided into aliquots, and stored
at  80 8C until use. The 50% tissue culture infectious dose
(TCID50) for each virus was determined by serial titration of
virus in Madin-Darby canine kidney (MDCK) cells and
calculated by the method developed by Reed and Muench
[22].
All experiments, including animal studies with infectious wt
H5 avian inﬂuenza viruses and the reassortant viruses, were
conducted using enhanced BSL-3 containment procedures in
laboratories approved for use by the USDA and Centers for
Disease Control and Prevention. Animal experiments were
approved by the National Institutes of Health Animal Care
and Use Committee. Experimental studies in chickens were
approved by the USDA (SEPRL) Animal Care and Use
Committee.
Plasmids and Transfections
cDNAs generated by RT-PCR from all six internal protein
gene segments of the AA ca were cloned into the plasmid
pAD3000. This plasmid is a derivative of plasmid pHW2000
[23] and contains pol I and pol II promoters for the
expression of vRNA and mRNA, respectively, from the full-
length viral gene segment insert. Similarly, cDNAs derived by
RT-PCR of the wt H5 genes, with a deletion of the sequence
encoding four basic amino acids at the HA1–HA2 cleavage
site (Table 1) and the wt N1 genes from the various H5N1
viruses were cloned into pAD3000. Sequences of all of the
inserts were conﬁrmed. For each H5N1 reassortant virus, the
six plasmid DNAs encoding the internal protein genes of the
AA ca were combined with the two plasmids encoding the
modiﬁed H5 gene and wt N1 gene, and Vero cells were
transfected with the eight-plasmid mixture by electropora-
Table 1. H5N1 ca Viruses without the Multibasic Amino Acid
Motif in the HA Require Trypsin for Plaque Formation in CEFs
Virus Amino Acid
Sequence near HA
Cleavage Site
a
Titer in CEFs log10 pfu/ml
With Trypsin Without Trypsin
AA ca PQIESRxGLF 7.0 ,1.0
H5N1 1997 wt PQRERRRKKRxGLF 8.5 8.5
H5N1 1997 ca PQRETRxGLF 5.0 ,1.0
H5N1 2003 wt PQRERRRKKRxGLF 8.5 8.5
H5N1 2003 ca PQRETRxGLF 6.7 ,1.0
H5N1 2004 wt PQRERRRKKRxGLF 8.7 8.6
H5N1 2004 ca PQRETRxGLF 8.0 ,1.0
b
aAn ‘‘x’’ indicates site of cleavage of the HA into HA1 and HA2 domains.
bSmall pinpoint foci typical of some low-pathogenicity avian influenza viruses were seen
without trypsin; however, no traditional plaques were evident.
DOI: 10.1371/journal.pmed.0030360.t001
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cloning by limiting dilution in SPF eggs, followed by
expansion in SPF eggs. Viruses that derive gene segments
from different parent viruses are referred to as reassortant
viruses whether they were generated by reverse genetics or
genetic reassortment.
Phenotypic Analysis of the Reassortant Viruses
The ts phenotype of the parent and reassortant viruses was
assessed by evaluating viral replication or cytopathic effects
(CPEs) in primary chick kidney cells at 33 8C and 39 8C. Viruses
that displayed 100-fold or greater reduction in viral titers at
high temperatures (  39 8C) compared with that observed at
the permissive temperature (33 8C) were considered ts.
The ca phenotype of the parent and reassortant viruses
were determined by comparing their infectivity in primary
chick kidney cells at 25 8C and 33 8C. Cold-adapted viruses
can replicate efﬁciently at low temperatures; the ca pheno-
type is deﬁned as a less than 100-fold reduction of virus titer
at 25 8C compared with that at 33 8C. Cells incubated at 33 8C
or 39 8C were examined for CPE 6 d postinfection and cells
incubated at 25 8C were examined for CPE 10 d postinfection.
The level of replication of the H5N1 wt and AA ca reassortant
viruses were within 10- to 100-fold of each other at 25 8C and
33 8C, indicating that the ca phenotype was not a discrim-
inating phenotype among these viruses; it has been observed
that several wt human inﬂuenza viruses are able to replicate
efﬁciently at 25 8C (unpublished data). It was therefore not
surprising that this observation was made with the wt H5N1
viruses. This is a reﬂection of the variability of the biology of
inﬂuenza viruses in nature.
Plaque Assay with and without Trypsin
Chick embryo ﬁbroblast (CEF) cells in 6-well tissue culture
plates were inoculated with 0.1 ml of virus serially diluted in
Leibovitz (L-15) medium. Virus was adsorbed to cells for 1 h,
with shaking every 15 min. Wells were overlaid with 1.8% w/v
Bacto agar (Difco, BD Diagnostic Systems, Palo Alto,
California, United States) mixed 1:1 with 23 Medium 199
containing antibiotics and fungizone, with or without 0.6 lg/
ml trypsin (Sigma, St. Louis, Missouri, United States). Plates
were inverted and incubated for 2–3 d. Wells were then
overlaid with 1.8% w/v Bacto agar mixed 1:1 with 23Medium
199 containing 0.05 mg/ml neutral red, and plates were
incubated for two additional days to visualize plaques.
Pathogenicity and Infectivity Studies in Chickens
To determine high or low-pathogenicity of the H5N1 ca
viruses, the standard intravenous lethality test was used [24].
Brieﬂy, the H5N1 wt (1997 wt, 2003 wt, and 2004 wt) and
reassortant H5N1 ca viruses were administered intravenously
togroupsofeight4-wk-oldWhitePlymouth Rockchickensat a
standarddoseof0.2mlofa1:10dilutionofstockvirusandwere
monitored formortality up to ten days postinfection (p.i.) [11].
To determine infectivity via a simulated natural route of
exposure, a separate group of chickens were inoculated
intranasally with 10
6 TCID50 of H5N1 wt and reassortant
H5N1 ca viruses. Oropharyngeal and cloacal swabs were
collected for virus isolation on day 3 p.i. or on the day of death
in chickens that died before day 3. On day 14 p.i., all surviving
chickens were euthanized and bled, and sera were tested for
evidence of seroconversion by agar gel precipitin assays.
Pathogenicity Studies in Mice
To determine the 50% lethal dose (LD50) of the different
H5N1 wt and reassortant ca viruses, groups of 4- to 6-wk-old
female BALB/c mice were anesthetized and infected intra-
nasally with serial 10-fold dilutions of the viruses in 50 ll.
Mice were monitored daily for 14 days p.i. for mortality.
To assess the ability of the viruses to replicate in different
organs, groups of 24 female BALB/c mice were inoculated
intranasally with 10
6 TCID50 of H5N1 2004 wt, H5N1 2004 ca,
or A/Beijing/95 ca (H1N1) viruses. Four mice from each group
were euthanized on days 2, 4, 6, 8, 10, and 12 p.i. However,
organs were collected only on days 2 and 4 from mice that had
received the H5N1 2004 wt virus, since none of these mice
survived beyond day 4. Lungs, nasal turbinates, and brains
were harvested, weighed, and homogenized in L-15 medium
containing antibiotics to make a 10% w/v tissue homogenate.
Tissue homogenates clariﬁed by low-speed centrifugation
were titered in 24- and 96-well culture plates containing
MDCK cells; titers are expressed as log10 TCID50/g of tissue.
Replication in Ferrets
The ability of H5N1 ca and wt viruses to replicate in ferrets
were compared. Groups of three 10- to 12-wk-old ferrets
(Harlan, Madison, Wisconsin, United States) were pre-bled
and tested by hemagglutination assay and were found to be
negative for antibodies to H3N2 inﬂuenza. Each ferret was
inoculated intranasally with 10
7 TCID50 of H5N1 ca vaccine
viruses or H5N1 wt viruses or AA ca in a volume of 1 ml (0.5
ml per nostril). Ferrets were monitored daily for clinical signs
of inﬂuenza infection, and body temperatures were recorded
twice daily. On day 3 postinoculation, ferrets were euthanized
and nasal turbinates, lung, and brain tissue were harvested.
The tissues were homogenized, serial 10-fold dilutions were
prepared, and 0.1 ml of each dilution was inoculated into
four 9- to 11-d-old embryonated SPF hen’s eggs. Eggs were
incubated at 33 8C for 72 h for the ca vaccine virus or 37 8C
for 24 h for wt virus. Allantoic ﬂuid from each egg was
subjected to hemagglutination assay using 0.5% turkey
erythrocytes. Virus titers were determined as 50% egg
infectious doses (EID50) per gram of tissue using the Reed-
Muench method.
Evaluation of Immunogenicity of the Vaccine Candidates
in Mice
Groups of 4- to 6-wk-old female BALB/c mice were
immunized with 50 ll containing 10
6 TCID50 of each
reassortant virus, and sera were collected from these mice 4
wk later. Some groups of mice received two doses of 50 ll
containing 10
6 TCID50 of H5N1 2004 ca 28 d apart, and sera
were collected 4 wk after the second dose. Serum samples
were tested for the titer of HAI antibodies by standard
methods using 4 HA units of wt virus in V-bottom 96-well
microtiter plates with 0.5% turkey erythrocytes or with a 1%
suspension of horse erythrocytes [25]. Neutralizing antibody
titers were also evaluated in these samples by a micro-
neutralization assay. Serial 2-fold dilutions of heat-inacti-
vated serum were prepared, beginning with a 1:10 dilution.
Equal volumes of serum and virus were mixed and incubated
for 60 min at room temperature. The residual infectivity of
the virus-serum mixture was determined in four wells per
dilution. Neutralizing titer was deﬁned as the reciprocal of
the highest dilution of serum that completely neutralized
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for MDCK cells. Infectivity was identiﬁed by the presence of
CPE on day 4.
Evaluation of the Efficacy of the Vaccine Candidates
Protection from lethality in mice. Groups of eight mice that
received either a single dose of 10
6 TCID50 of the H5N1 ca
vaccine candidate or L-15 medium (mock-immunized) were
challenged with 50, 500, and 5,000 LD50 of either the H5N1
1997 wt or the H5N1 2004 wt virus. The H5N1 2003 wt virus
was not used in these studies because it was not lethal for
mice. In addition, mice that received a single dose of H5N1
2004 ca virus were also challenged with two additional, more
current antigenic variant H5N1 viruses that were isolated in
2005, A/VN/JPHN30321/2005 (H5N1) and A/Indonesia/05/2005
(H5N1). The mice were monitored daily for 21 d p.i.
Protection from replication of the challenge virus in the
respiratory tract in mice. The level of pulmonary viral
replication was also evaluated and compared in separate
groups of mice that received one or two doses of the H5N1
2003 wt or H5N1 2004 ca vaccine viruses. Mice that had
received a single dose of 10
6 TCID50 of the immunizing virus
were challenged with 10
5 TCID50 of H5N1 1997 wt, H5N1
2003 wt, or H5N1 2004 wt viruses on day 28 p.i. Lungs were
harvested 2 d later, homogenized, and titrated on MDCK cells
as previously described. Mice that received two doses of the
immunizing virus four weeks apart were challenged with the
H5N1 wt viruses on day 56 p.i., their lungs were harvested 2
days later and were homogenized and titered on MDCK cells.
Log-transformed viral titers were compared using the Mann-
Whitney U test.
In a separate experiment, mice that received two doses of
10
6 TCID50 of H5N1 1997 ca, H5N1 2003 ca, or H5N1 2004 ca
viruses 4 wk apart were challenged on day 56 p.i. with 10
5
TCID50 of homologous and heterologous wt H5N1 viruses,
including A/Indonesia/05/2005 (H5N1). The lungs and brains
were harvested from these mice 4 d later and were
homogenized and titered on MDCK cells.
Protection from replication of challenge viruses in ferrets.
Groups of nine 6-wk old ferrets were inoculated intranasally
with 10
7 TCID50 of either H5N1 1997 ca, H5N1 2004 ca, or L-
15 medium (mock-immunized), in a volume of 0.5 ml/nostril,
on days 0 and 28. In order to determine whether the internal
protein genes of the AA ca virus contributed to protection, an
additional group of ferrets immunized with A/New Caledonia/
99 ca (H1N1) was included. Serum samples were collected
from ferrets on day 18 after the second vaccination, and HAI
antibody titers against the relevant challenge virus were
determined using horse erythrocytes. At 1 mo after the
second immunization, ferrets were challenged intranasally
with 10
7 TCID50 of either H5N1 1997 wt, H5N1 2004 wt, or A/
Indonesia/05/2005 (H5N1). Ferrets that had been immunized
with A/New Caledonia/99 ca (H1N1) were challenged only with
H5N1 1997 wt. At 3 d postchallenge, ferrets were euthanized,
and brain, lungs, and nasal turbinates were harvested and
homogenized. Tissue homogenates were titered on MDCK
cells.
Log-transformed viral titers were compared using the two-
tailed Student’s t-test. The correlation of HAI titer with viral
titer in the various tissues was determined by calculation of
the Spearman rank correlation coefﬁcient.
Results
Generation of H5N1 ca Viruses
Reassortant viruses with a modiﬁed H5 HA gene and N1
NA gene derived from H5N1 1997, 2003, and 2004 viruses and
remaining gene segments from AA ca were generated by
reverse genetics [23]. The HA gene was modiﬁed by replacing
the multibasic amino acid motif with the sequence seen in
avian inﬂuenza viruses that are not highly pathogenic in
chickens (Table 1) [11]. The nucleotide sequence of each gene
segment of the three viruses was identical to the sequence of
the corresponding gene insert in the parent viruses, with the
exception of a single coding change each in the PA gene
segment of the 2004 ca and 1997 ca viruses. The ﬁve mutations
in the AA ca virus that specify ts and att phenotypes were
present in the H5N1 ca viruses [26,27]. The H5N1 ca vaccine
viruses were antigenically similar to their respective wt parent
viruses by HAI test with postinfection ferret antisera
(unpublished data). The phenotypic characteristics of the
H5N1 ca viruses were also evaluated in vitro and in vivo in
chickens, mice, and ferrets.
In Vitro Phenotypes: Trypsin Dependence and
Temperature Sensitivity
The HA gene in the H5N1 ca viruses differed from the HA
gene in the corresponding wt parent viruses by the absence of
the multibasic amino acid cleavage site. The presence of this
motif in an inﬂuenza A virus of the H5 or H7 subtype confers
the ability to plaque efﬁciently in CEF cells in the absence of
trypsin [28–30]; the H5N1 1997 wt, H5N1 2003 wt, and H5N1
2004 wt viruses demonstrated this property (Table 1). The
H5N1 ca viruses failed to plaque in CEF cells in the absence of
trypsin, consistent with the absence of the multibasic cleavage
site motif in the HA protein (Table 1) [29].
Extensive experience with H1N1 and H3N2 reassortant
viruses and an H9N2 reassortant virus that derived the six
internal protein gene segments from the AA ca virus has
shown that the ts and att phenotypes are speciﬁed by these
gene segments [19,26,27,31,32]. The H5N1 ca viruses and the
Table 2. Evaluation of the ts Phenotype of Wild-Type and
Reassortant H5N1 ca Influenza Viruses
Virus Mean Titer
6 Standard Error
(SE) (log10 TCID50/ml)
ts Phenotype
a
33 8C3 9 8C
AA wt 8.6 6 0.11 7.2 6 0.12  
AA ca 9.0 6 0.15 4.3 6 0.05 þ
H5N1 1997 wt 8.0 6 0.25 8.0 6 0.03  
H5N1 1997 ca 6.0 6 0.17 ,3.2
b þ
H5N1 2003 wt 7.9 6 0.15 8.3 6 0.05  
H5N1 2003 ca 6.4 6 0.20 4.2 6 0 þ
H5N1 2004 wt 8.1 6 0.05 8.5 6 0.06  
H5N1 2004 ca 7.4 6 0.06 ,3.7
b þ
aThe ts phenotype was determined by virus titration in primary chick kidney cells at 33 8C
and 39 8C. A virus is considered ts when the difference in the mean TCID50 of the virus at
33 8C and 39 8C is 100-fold or greater. Virus titers are presented as mean 6 SE
(log10TCID50/ml).
bBelow limit of detection.
DOI: 10.1371/journal.pmed.0030360.t002
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in contrast, the wt H5N1 parent viruses replicated equally
well at 33 8C and 39 8C (Table 2). Thus, the three H5N1 ca
viruses demonstrated the ts phenotype.
Attenuation In Vivo in Chickens, Mice, and Ferrets
Level of attenuation in chickens following intravenous
administration. The H5N1 1997 wt, H5N1 2003 wt, and H5N1
2004 wt viruses were highly pathogenic for chickens, ﬁndings
that are consistent with the presence of multibasic amino acid
motif in the HA [28–30] (Table S1). The H5N1 ca viruses were
no longer lethal for chickens in the standard intravenous
pathogenicity test, consistent with the absence of the multi-
basic cleavage site motif in the HA protein (Table S1) [29].
Level of attenuation in chickens following intranasal
administration. In order to determine whether H5N1 ca
viruses would infect and cause disease in chickens exposed to
the virus through a more natural route, the H5N1 wt and ca
viruses were administered to chickens intranasally. The H5N1
wt viruses were recovered from cloacal and oropharyngeal
swabs on day 3 following virus administration, and the
infection was lethal for 8 of 8 chickens (Table S1). The H5N1
ca viruses were not lethal for chickens and did not appear to
infect the chickens following intranasal administration, as
indicated by the absence of detectable infectious virus in
cloacal or oropharyngeal swabs and the absence of an
antibody response to the virus (Table S1). The poor infectivity
of the H5N1 ca viruses in chickens is likely the result of an
inability of these ts viruses to replicate at the high body
temperature of chickens (40–41 8C) and suggests that their
use would not pose a threat to the poultry industry.
Lethality in mice. When administered intranasally, the
H5N1 1997 wt and H5N1 2004 wt viruses were highly lethal for
mice (LD50 values of 10
2 and 10
0.4 TCID50, respectively),
whereas the H5N1 2003 wt virus was lethal for a few mice at a
very high dose (LD50   10
6 TCID50). Lethality for mice was
completely abrogated in the three H5N1 ca viruses; none of
the mice died even at the highest dose of virus administered
(LD50 . 10
7 TCID50).
Level of replication in the respiratory tract of mice. The
level of replication of the H5N1 1997 ca and H5N1 2004 ca
viruses was lower than that of the corresponding H5N1 wt
viruses in the upper and lower respiratory tract of mice
(Table 3), and the differences in titer were similar to or
exceeded the difference between the titers achieved in mice
infected with the AA wt and ca viruses. The level of replication
of the H5N1 2003 wt and ca virus did not differ signiﬁcantly in
the respiratory tract (Table 3 and unpublished data for days 2
and 4). The reasons for this observation are not clear, but it
may be the result of a partial attenuation of the H5N1 2003 wt
virus, which does not replicate as efﬁciently in the respiratory
tract of mice as the H5N1 1997 wt and H5N1 2004 wt viruses,
and may also partly explain why the H5N1 2003 wt virus was
not lethal for mice in some studies [33], although other
investigators have found the H5N1 2003 wt virus to be lethal
in mice [16].
Level of replication of H5N1 2004 ca virus in the brains of
mice following intranasal administration. Previous studies
have established that some of the H5N1 wt viruses can be
detected in the brains of mice following intranasal admin-
istration [33–38]. In order to determine whether the
modiﬁcations in the HA gene and the presence of the
internal protein gene segments from the AA ca virus altered
the neurotropism of the H5N1 2004 ca reassortant viruses, we
administered the H5N1 2004 ca virus, the H5N1 2004 wt virus,
and an H1N1 ca virus (as a control) to mice by the intranasal
route and determined the ability of these viruses to replicate
in the respiratory tract or brain. A single dose of 10
6 TCID50
of each virus was administered intranasally, and eight mice
from each group were sacriﬁced on alternate days from day 2
to day 12 p.i. (Figure 1). The H5N1 2004 wt virus was detected
in the brains of mice on days 2 and 4 p.i. with mean titers of
Table 3. The H5N1 ca Viruses Are Restricted in Replication in the
Respiratory Tract of Mice
Tissue Virus Mean Virus
Titer 6 SE on
Day 3 p.i.
a
Mean Log10
Reduction in
Titer of ca
Compared to wt
wt ca
Lungs AA/6/60 6.2 4.5 6 0.1 1.7
b
H5N1 1997 7.0 6 0.12 4.1 6 0.33 2.9
b
H5N1 2003 6.3 6 0.21 5.1 6 0.06 1.2
b
H5N1 2004 7.0 6 0.14 4.1 6 0.22 2.9
b
Nasal turbinates AA/6/60 4.7 6 0.18 2.5 6 0.25 2.2
b
H5N1 1997 5.5 6 0.18 2.5 6 0.25 3.0
b
H5N1 2003 3.0 6 0.17 2.5 6 0.25 0.5
c
H5N1 2004 4.8 6 0.39 2.6 6 0.3 2.2
b
Lungs and nasal turbinates from groups of four mice were harvested on days 2, 3, and 4
postinfection. Data from day 3 are presented. Virus titers are expressed as mean 6 SE
log10TCID50/g of tissue, and mean titers from groups of mice were used to determine the
level of restriction of replication of the ca virus compared to the corresponding wt virus.
a10
6 TCID50 of wt or corresponding ca virus was administered intranasally to mice.
bp ¼ 0.02 by Mann-Whitney U-test.
cp ¼ 0.47 by Mann-Whitney U-test.
DOI: 10.1371/journal.pmed.0030360.t003
Figure 1. Replication of H5N1 2004 ca and 2004 wt Viruses in the Brains
of Mice
The H5N1 2004 ca virus, unlike the H5N1 2004 wt parent virus, is
undetectable in the brain. Influenza A/Beijing/95 ca, an H1N1 ca
reassortant virus, was also undetectable in the brains of mice. The lower
limit of detection is indicated by the dashed horizontal line. Four mice
per group were euthanized at each time point (days 2, 4, 6, 8, 10, and 12).
Data from days 6 through 12 are combined in the figure because virus
was not detected in any of the brain tissues harvested on these days.
DOI: 10.1371/journal.pmed.0030360.g001
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1.8 and 10
4.9 TCID50/g, respectively, but the H5N1 2004 ca
virus and the ca virus were not. It should be noted that
although the H5N1 2004 ca virus and the H1N1 ca virus were
not recovered from the brain, they were isolated from the
lungs and nasal turbinates (unpublished data), indicating that
the H5N1 ca and H1N1 ca viruses replicated in the respiratory
tract, but did not spread to the central nervous system of
mice. Further studies are warranted to delineate the relative
contribution(s) of the modiﬁed HA and the internal genes of
AA ca to the observed lack of neurotropism of the H5N1 2004
ca virus. A similar lack of neurotropism of the H5N1 1997 ca
virus was also observed (unpublished data).
Level of replication of H5N1 2004 ca and H5N1 1997 ca in
ferrets. The levels of replication of the H5N1 2004 ca and
H5N1 1997 ca viruses compared to their respective wt
parental H5N1 viruses in ferrets were determined. The
H5N1 2004 ca and H5N1 2004 wt viruses replicated in the
upper respiratory tract of ferrets but the H5N1 2004 ca virus
was not detected in the lower respiratory tract or brain of any
of the ferrets. In contrast, the H5N1 2004 wt virus replicated
in the lungs and brains of ferrets (Table 4). The H5N1 1997 wt
virus replicated efﬁciently in the upper respiratory tract of
ferrets, and the H5N1 1997 ca virus was detected in the nasal
turbinates of two out of three ferrets. The H5N1 1997 ca virus
was not detected in the lower respiratory tract or brain of
ferrets, unlike the H5N1 1997 wt virus, that was isolated from
the lungs and brains of all three ferrets (Table 4). The H5N1
1997 ca and H5N1 2004 ca viruses were highly restricted in
replication in the upper respiratory tract of ferrets compared
to the corresponding wt viruses. The attenuation of the H5N1
2004 ca and H5N1 1997 ca vaccine viruses in the respiratory
tract of ferrets was consistent with the observations in mice.
Thus, the H5N1 ca viruses demonstrated the properties
predicted by the genetic modiﬁcations of removing the
multibasic amino acid motif in the HA and the introduction
of the internal gene segments from the AA ca virus. Studies
were next undertaken to determine the immunogenicity and
efﬁcacy of these viruses as candidate vaccines.
Immunogenicity of the H5N1 ca Virus Vaccine Candidates
Each of the H5N1 ca candidate vaccines was administered
intranasally to mice at a dose of 10
6 TCID50, and serum
antibody responses at 28 d postimmunization were measured
by HAI and microneutralization assays. The nonlethal H5N1
2003 wt virus was administered to a group of mice as a
positive control. A single dose of vaccine was poorly
immunogenic in mice, with low antibody responses in both
assays (Table 5). However, ELISA antibodies were detected in
the serum against recombinant H5 HA (unpublished data).
The titer and cross-reactivity of the neutralizing and HAI
antibody response was greater 4 wk after a second dose of
vaccine administered 28 d after the ﬁrst dose (Table 6),
although replication of the second dose of vaccine was not
detected in the respiratory tract (unpublished data). The
H5N1 2003 ca and wt viruses elicited higher antibody titers
against the homologous virus than the H5N1 1997 ca and
H5N1 2004 ca viruses; these ﬁndings are consistent with
previous observations that identiﬁed the amino acid aspar-
agine at position 223 in the HA as a determinant of enhanced
immunogenicity of the H5N1 2003 viruses [39].
An additional study was performed to determine the
immunogenicity of one versus two intranasal doses of
vaccine. In this study, one group of eight mice received a
dose of vaccine on day 0, a second group received vaccine on
Table 4. The H5N1 ca Viruses Are Attenuated in Ferrets
Tissue Virus Mean Virus
Titer 6 SE on
Day 3 p.i.
a
Mean Log10
Reduction
in Titer of ca
Compared to wt
wt ca
Lungs AA/6/60 ND  1.5
b NA
H5N1 2004 3.3 6 0.4  1.5  1.8
c
H5N1 1997 3.0 6 0.8  1.5  1.5
Nasal turbinates AA/6/60 ND 5.3 6 0.3 NA
H5N1 2004 7.8 6 0.5 4.1 6 0.6 3.7
c
H5N1 1997 7.4 6 0.5 1.8 6 0.1 5.6
c
Brain AA/6/60 ND  1.5 NA
H5N1 2004 3.8 6 0.6  1.5  2.3
c
H5N1 1997 3.9 6 0.5  1.5  2.4
c
aGroups of three ferrets were inoculated intranasally with 10
7 TCID50 of indicated virus
and nasal turbinates and lungs were harvested on day 3 p.i. Titers are expressed as the
mean 6 SE log10 EID50/g in tissue homogenates.
bBelow lower limit of detection.
cp , 0.02 by Student’s t-test on log-transformed titers.
NA, not applicable; ND, not done.
DOI: 10.1371/journal.pmed.0030360.t004
Table 5. Serum Neutralizing and HAI Antibodies Elicited in Mice Following a Single Intranasal Dose of H5N1 ca Vaccine
Immunizing Virus Reciprocal Geometric Mean (Range) Serum
Neutralizing Antibody Titers against Indicated Virus
a
Reciprocal Geometric Mean (Range) Serum HAI
Antibody Titers against Indicated Virus
b
H5N1 1997 wt H5N1 2003 wt H5N1 2004 wt H5N1 1997 wt H5N1 2003 wt H5N1 2004 wt
H5N1 1997 ca 16.7 (10–40) 10 10 6.3 (5–10) 5.6 (5–20) 5
H5N1 2003 ca 10 59.2 (20–113) 10 5 53.4 (20–160) 5
H5N1 2004 ca 11 (10–16) 15.2 (10–25) 14.2 (10–57) 5.3 (5–10) 6.7 (5–20) 5.3 (5–10)
H5N1 2003 wt 10 93.3 (63–160) 10 5 105.6 (80–640) 5
Mice received a single intranasal dose of 10
6 TCID50 of the immunizing virus. Serum was obtained four weeks after immunization. HAI titers were determined using turkey erythrocytes.
Values represent reciprocal geometric mean antibody titers from four mice per group. Antibodies were not detectable in preimmunization sera. Antibody titers against homologous virus
are shown in red.
aAn undetectable serum neutralizing antibody titer was assigned a value of 10.
bAn undetectable HAI antibody titer was assigned a value of 5.
DOI: 10.1371/journal.pmed.0030360.t005
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0 and received vaccine on day 28. Serum was collected from
all of the mice on days 27 and 54. The HAI antibody response
4 wk after a single dose of the H5N1 2004 ca vaccine was low.
Responses to a single dose of vaccine continued to rise over 2
mo, however, and titers achieved 4 wk after a second dose of
vaccine were higher than in mice that received a single dose
of vaccine 8 wk earlier (Table 7). The pattern of HAI
responses was the same whether the assay was performed with
turkey or horse erythrocytes, but the HAI assay was more
sensitive when performed with horse erythrocytes (Table 7).
Efficacy of the H5N1 ca Virus Vaccine Candidates
Protection from lethality in mice. All of the mice immu-
nized with H5N1 ca vaccine viruses survived challenge with
50, 500, or 5,000 LD50 of homologous or heterologous H5N1
wt viruses, despite an undetectable neutralizing and HAI
antibody response in mice 28 d following a single intranasal
dose of 10
6 TCID50 of the vaccines (Figure 2). Mock-
immunized mice died between days 6 and 10 p.i. The AA ca
virus that was the source of the six internal protein genes of
the H5N1 ca vaccine viruses provided partial heterosubtypic
protection from lethality following challenge with the H5N1
1997 and H5N1 2004 wt viruses. This protection decreased
with increasing doses of challenge virus (Figure 2). The
mechanism of protection from lethality that was observed in
the absence of detectable serum neutralizing antibodies
against H5N1 viruses is under investigation.
Protection from challenge virus replication in the respira-
tory tract of mice. Although mice that received a single dose
of vaccine were protected from lethality, they were not fully
protected from replication of the H5N1 1997 wt or H5N1
2004 wt virus in the respiratory tract (Figure 3A and 3B). The
titer of the challenge virus detected in the respiratory tract of
mice immunized with the H5N1 2004 ca vaccine was
signiﬁcantly lower than in mock-immunized mice or mice
immunized with the AA ca virus (Figure 3A and 3B), and the
challenge virus did not spread to the brain (unpublished
data). However, complete protection from pulmonary virus
replication was not seen following a single dose of vaccine
when mice were challenged with 10
6 TCID50 or even 10
2
TCID50 of H5N1 1997 wt or H5N1 2004 wt virus (unpublished
data). Incomplete protection from pulmonary virus replica-
tion is consistent with the low neutralizing and HAI antibody
response 28 d following a single dose of vaccine (Table 5).
Interestingly, a single dose of the H5N1 2004 ca virus
provided complete protection from replication of the
H5N1 2003 wt virus in the respiratory tract (Figure 3A and
3B). In consonance with a higher level of neutralizing and
HAI antibody response following two doses of vaccine (Tables
6 and 7), complete or near-complete protection from virus
replication was observed in the respiratory tract of mice
following two doses of vaccine (Figure 3C and 3D).
Efficacy of the H5N1 ca Virus Vaccine Candidates against
Antigenic Variant wt H5N1 Viruses Isolated in 2005
Efﬁcacy in mice. The H5N1 ca vaccines were also evaluated
for their efﬁcacy against challenge with newly emerged and
antigenically distinct H5N1 strains, A/VN/JPHN30321/2005
(H5N1), designated a clade 1 virus, and A/Indonesia/5/2005
(H5N1), a clade 2 virus by the CDC [4]. A single intranasal
dose of 10
5 TCID50 of the H5N1 2004 ca vaccine provided
complete protection from lethality following challenge (10
5
TCID50) with A/VN/JPHN30321/2005 (H5N1) and A/Indonesia/
5/2005 (H5N1) (unpublished data). Moreover, mice that
received two doses (10
6 TCID50/dose) of the H5N1 ca vaccines
were protected from viral replication in the lungs and brains
following challenge with 10
5 TCID50 of A/Indonesia/5/2005
(H5N1) (Figure 4). This protection from viral replication was
associated with high neutralizing antibody titers against A/
Indonesia/5/2005 (H5N1) that were detected in the sera of all
immunized mice that received two doses of the vaccines
(geometric mean neutralizing antibody titers of 90, 174, and
104 for mice that were immunized with two doses of the
H5N1 1997 ca, H5N1 2003 ca, and H5N1 2004 ca, respectively).
Efﬁcacy in ferrets. Ferrets that received two doses (10
7
TCID50/dose) of the H5N1 ca vaccines were completely
protected from viral replication in the lungs following
homologous or heterologous challenge; the latter included
challenge with 10
7 TCID50 of A/Indonesia/5/2005 (H5N1)
(Figure 5). Virus titers in the nasal turbinates of ferrets
immunized with H5N1 2004 ca or H5N1 1997 ca were
statistically signiﬁcantly lower than those of the mock-
immunized ferrets following challenge with H5N1 2004 wt
Table 6. Serum Neutralizing Antibodies Elicited in Mice
Following Two Doses of H5N1 ca Vaccine
Immunizing
Virus
Reciprocal Geometric Mean Serum Neutralizing
Antibody Titers against Indicated Virus
a
H5N1 1997 wt H5N1 2003 wt H5N1 2004 wt
H5N1 1997 ca 419 253 17
H5N1 2003 ca 19 1,056 61
H5N1 2004 ca 160 528 388
H5N1 2003 wt 27 1,881 123
Mice received two intranasal doses of 10
6 TCID50 of the immunizing virus. Sera were
obtained 4 wk after each immunization. Antibodies were not detected in preimmuniza-
tion sera.
aFifteen mice per group were immunized. Sera from five mice were pooled for testing and
three pools were tested for each group. Values represent the geometric mean
neutralizing antibody titer of the three pools. Antibody titers against homologous virus
are shown in red.
DOI: 10.1371/journal.pmed.0030360.t006
Table 7. Geometric Mean HAI Antibody Titers in Mice Immu-
nized with One or Two Doses of the H5N1 2004 ca Influenza
Virus
Vaccine Regimen Geometric Mean HAI Titer
against H5N1 2004 wt with
Turkey (Horse) Erythrocytes
a
Dose 1
(Day 0)
Dose 2
(Day 28)
Prebleed Post-Dose 1
(Day 27)
Post-Dose 2
(Day 54)
Mock H5N1 2004 ca 5 (5) 5 (5) 6 (40)
H5N1 2004 ca Mock 5 (5) 5 (40)
b 40 (211)
b,c
H5N1 2004 ca H5N1 2004 ca 5 (5) 10 (30) 160 (485)
c
aAn undetectable titer was assigned a value of 5.
bp ¼ 0.003 by two-tailed Student’s t-test (on log-transformed titers).
cp ¼ 0.03 by two-tailed Student’s t-test (on log-transformed titers).
DOI: 10.1371/journal.pmed.0030360.t007
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brains of these ferrets at statistically signiﬁcantly lower titers
than in mock-immunized animals. A possible explanation for
the presence of virus in the brains of these ferrets is that
challenge inoculum was present in the olfactory bulb. Since
different areas of the brain were not processed separately,
this cannot be conﬁrmed. There was a strong correlation
between the titers of virus in these tissues and the immune
response at day 18 after the second immunization (p ,
0.000001 and p ¼ 0.0035, respectively).
Thus, immunization with two doses of an H5N1 ca vaccine
possessing the surface glycoprotein genes of the 1997 virus
provided a high level of protection in mice and ferrets against
H5N1 viruses that had evolved in nature over 8 y and that
belonged to different phylogenetic clades.
Discussion
Reverse genetics technology [23,40,41], used to generate
inﬂuenza viruses from cells cotransfected with plasmids
expressing inﬂuenza virus gene segments, has been applied
to vaccine development since 1998 [11,12,15]. The technol-
ogy is especially valuable for the generation of vaccines
against HPAI viruses because it permits modiﬁcation of
gene(s) to remove speciﬁc virulence motifs such as the
highly cleavable multibasic amino acid motif in the HA
protein. The generation of a candidate vaccine for human
use requires transfection of cells that are qualiﬁed for use
in generation of vaccines for use in humans; subsequent
ampliﬁcation and biological cloning are carried out in SPF
embryonated hen’s eggs. The H5N1 viruses that were
targeted for vaccine development were selected in con-
sultation with public health authorities and represent
viruses isolated in 1997, 2003, and 2004 from human cases
of H5N1 infection. These wt viruses were antigenically
distinguishable from each other using postinfection ferret
antisera [4]. Live, attenuated vaccine candidates were
generated against each of the three wt viruses using a
common strategy. The HA gene of each of the live,
attenuated vaccine candidates was modiﬁed to remove the
multibasic virulence motif as described in earlier publica-
tions [11,12,15], and the six internal protein genes were
derived from the highly attenuated AA ca donor virus, as
described in [15]. The H5N1 ca candidate vaccine viruses
displayed the ts and att phenotypes that are speciﬁed by the
internal protein genes of the AA ca [26,27], and the viruses
failed to plaque in CEF cells in the absence of trypsin,
consistent with the absence of the multibasic cleavage site
in the HA.
The safety of the H5N1 ca vaccine viruses was established
in mice and ferrets. The H5N1 1997 ca and H5N1 2004 ca
viruses were not lethal for mice, and when compared with
Figure 2. Survival of Mice Immunized with a Single Dose of H5N1 ca Vaccine Candidates Following Lethal Challenge with H5N1 1997 wt or H5N1 2004
wt Viruses
Groups of eight mice that received a single dose of 10
6 TCID50 of the H5N1 1997 ca (&), H5N1 2003 ca (m), H5N1 2004 ca ( n), or AA ca (* *) viruses, or
were mock-immunized (L-15 medium; ¤) were challenged with the H5N1 1997 wt (A–C) or H5N1 2004 wt virus (D–F) at 50 (A and D), 500 (B and E), or
5,000 (C and F) LD50. The mice were monitored daily for 21 d p.i. Immunization with the H5N1 1997 ca, H5N1 2003 ca, and H5N1 2004 ca viruses
resulted in 100% survival of the mice following challenge, so the symbols for these groups are superimposed.
DOI: 10.1371/journal.pmed.0030360.g002
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replication in the upper and lower respiratory tract of
mice. The acquisition of the six AA ca internal protein
genes by the H5N1 1997 wt and H5N1 2004 wt viruses
attenuated these viruses for mice. The level of restriction of
replication of the H2N2 and H5N1 wt viruses speciﬁed by
the six AA ca internal protein genes was comparable,
indicating that the acquisition of these genes reproducibly
attenuated the H5N1 avian inﬂuenza viruses for mice. This
has also been seen for an H9N2 avian inﬂuenza virus [32].
Thus, the observation that the H5N1 2003 wt and ca viruses
replicated to similar levels in mice was unexpected. Since
the H5N1 2003 wt virus itself replicated to a low level and
exhibited minimal lethality, it is reasonable to suggest that
this H5N1 wt virus contains sequences that restrict its
replication in mice. If these sequences occur in one or
more of the internal protein genes of the virus, it is not
surprising that substitution of these attenuating sequences
with the six internal protein genes of the AA ca virus did
not result in further attenuation. This suggestion will need
experimental veriﬁcation. The att phenotype was also seen
in the ferret model: the H5N1 2004 wt and H5N1 1997 wt
viruses replicated to high titers in the upper and lower
respiratory tract, while the H5N1 2004 ca and H5N1 1997
ca viruses were attenuated in the nasal turbinates and were
undetectable in the lungs and brain of ferrets. The similar
levels of attenuation displayed by H5N1 2004 ca and H5N1
1997 ca in mice and ferrets indicate that either animal
model could be used to demonstrate the attenuation of
reassortant viruses bearing internal protein genes from the
AA ca donor virus. Thus, the H5N1 ca viruses were safe for
the respiratory tract of mice and ferrets, and additional
studies indicated that the H5N1 2004 ca virus did not
spread from the respiratory tract of mice or ferrets to the
brain, while the H5N1 2004 wt virus readily infected the
brains of these animals. The H5N1 ca viruses, in contrast to
the H5N1 wt viruses, were not lethal for chickens in the
standard intravenous pathogenicity test or when adminis-
Figure 3. Replication of H5N1 wt Challenge Viruses in Mice Immunized with One or Two Doses of H5N1 ca Viruses
(A and B) Mice that received a single dose of 10
6 TCID50 of the immunizing virus were challenged with 10
5 TCID50 of H5N1 1997 wt, H5N1 2003 wt, or
H5N1 2004 wt viruses on day 28 p.i. Replication of challenge virus is shown in the lungs (A) and nasal turbinates (B).
(C and D) Mice that received two doses of the immunizing virus 4 wk apart were challenged with the H5N1 wt viruses on day 56 p.i. Replication of
challenge virus is shown in the lungs (C) and nasal turbinates (D).
Lungs were harvested 2 d following challenge, homogenized, and titrated on MDCK cells. Groups of mock-immunized (L-15) mice and mice immunized
with the nonlethal 2003 wt virus (single dose) or with AA ca were included as control groups. Four mice were evaluated in each group. The lower limit
of detection is indicated by the dashed horizontal line. Log-transformed viral titers were compared using the Mann-Whitney U test. * p   0.05
compared to mock-immunized mice.
DOI: 10.1371/journal.pmed.0030360.g003
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pose a threat to agriculture. However, the H5N1 ca viruses
would not be suitable candidate vaccines for use in poultry,
because they fail to replicate and to induce an antibody
response in chickens.
Despite a high level of replication in the respiratory tract
of mice, the H5N1 ca candidate vaccine viruses were weakly
immunogenic in mice following a single dose. Neutralizing
antibody titers induced following a single dose continued to
rise for 1–2 mo following immunization, indicating that the
functional antibody response develops slowly in mice. A
second dose of vaccine resulted in a signiﬁcant boost in
antibody titer and in cross-reactivity of the antibody with
antigenically distinguishable H5N1 viruses. If similar anti-
body kinetics are observed in clinical trials, a single dose of
vaccine may sufﬁce to confer protection, but the protection
may be slow to develop. A boost in antibody titers followed a
second dose of vaccine despite the fact that replication of the
second dose of vaccine was not detected. Thus, a delayed
maturation of functional antibody occurred in response to
the H5N1 ca vaccine viruses compared to that seen with other
inﬂuenza A viruses [32,42]. The delayed antibody response
had a correlate in efﬁcacy studies.
A single dose of H5N1 ca vaccines provided complete
protection from lethality following challenge with homol-
ogous and heterologous H5N1 wt viruses and prevented
systemic spread of the wt challenge viruses to the brain. A
single dose of H5N1 ca vaccines also resulted in statistically
signiﬁcant restriction of replication of the wt challenge
viruses in the lungs that greatly exceeded that induced by
infection with the heterosubtypic AA ca (H2N2) virus, thus
indicating that this protection was HA- and NA-speciﬁc.
However, a single dose of vaccine did not induce complete
protection against replication of challenge virus in the
respiratory tract. In a clinical setting, this partial protection
in mice may translate to protection from severe illness and
death in humans. Two doses of the H5N1 ca candidate
vaccine viruses induced high titers of antibody and
provided complete protection from pulmonary replication
of homologous and heterologous H5N1 wt viruses. Repli-
cation of the second dose of vaccine virus could not be
detected, but antigenic stimulation was sufﬁcient to provide
a boost in immune response. Two doses of the H5N1 ca
vaccine in mice and in ferrets provided complete protec-
tion from pulmonary replication of homologous and
heterologous H5N1 wt viruses, including A/Indonesia/05/
2005 (H5N1). In mice, two doses of the H5N1 ca vaccine
provided complete protection from systemic dissemination
of challenge virus. Virus was detectable in the brains of
ferrets following challenge with a high dose of H5N1 wt
virus, but viral titers were statistically signiﬁcantly reduced
compared to mock-immunized animals. Similar to the
observations in mice immunized with the AA ca virus, the
protection in ferrets against pulmonary replication of
challenge virus afforded by the H5N1 ca vaccines exceeded
that observed when ferrets were immunized with an H1N1
ca virus bearing the same AA ca internal protein genes,
which suggests that the protection is speciﬁc to the H5 HA.
It is not possible to predict the evolution of the H5 HA
or to predict which strain, if any, will become pandemic.
Therefore, an H5N1 vaccine should elicit a cross-protective
immune response against a range of H5N1 viruses,
including newly emerged strains. In addition, a pandemic
vaccine needs to be preselected before the pandemic virus
emerges in the population and characterized in humans for
safety and immunogenicity, since it is highly unlikely that a
Figure 4. Immunization of Mice with Two Doses of H5N1 ca Viruses Provides Protection against Replication of Homologous and Heterologous H5N1 wt
Viruses in the Lungs
Mice that received two doses of 10
6 TCID50 of H5N1 1997 ca, H5N1 2003 ca, or H5N1 2004 ca viruses 4 wk apart were challenged on day 56 p.i. with 10
5
TCID50 of homologous and heterologous H5N1 wt viruses, including A/Indonesia/05/2005, a clade 2 H5N1 wt virus. The lungs were harvested from
these mice 4 d later and were homogenized and titered on MDCK cells. Four mice were evaluated in each group. The lower limit of detection is
indicated by the dashed horizontal line. * p , 0.02 compared to mock-immunized mice.
DOI: 10.1371/journal.pmed.0030360.g004
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rapidly enough to thwart spread of a pandemic strain. The
assumption underlying this approach is that the preselected
pandemic vaccine virus can prevent disease caused by
antigenically and genetically divergent viruses belonging to
the same subtypes that appear in nature. In the present
study, we were able to directly evaluate this assumption,
and our data on the H5N1 ca vaccines are very encouraging
in this regard. A single dose of an H5N1 ca vaccine
containing the 1997 H5 HA provided complete protection
from lethality in mice following challenge with homologous
and heterologous H5N1 wt viruses, including a clade 2 virus
isolated from Indonesia in 2005. Two doses of the H5N1 ca
vaccine provided complete protection from pulmonary
replication in mice and ferrets and systemic dissemination
of homologous and heterologous H5N1 wt viruses in mice.
The high level of efﬁcacy of the H5N1 1997 ca virus against
challenge with antigenically and genetically diverse H5N1
wt viruses isolated over a span of 8 y suggests that the
H5N1 viruses are evolving in nature to infect wild birds
and domestic poultry, and not predominantly to evade
antibodies as they do in humans. If the vaccine candidates
described in this paper elicit a broadly cross-reactive
protective immune response in humans, they would
support the approach of developing one or two pandemic
vaccine candidates for each subtype (H4 through H16) that
are able to induce a broadly protective immune response to
wt viruses within that subtype. The present ﬁndings serve to
Figure 5. Efficacy in Ferrets of Two Doses of H5N1 ca Viruses against Challenge with Homologous and Heterologous H5N1 wt Viruses
Ferrets were immunized with two doses of 10
7 TCID50 of H5N1 1997 ca or H5N1 2004 ca viruses 1 mo apart and challenged 1 mo later with 10
7 TCID50
of either H5N1 1997 wt, H5N1 2004 wt, or A/Indonesia/05/2005 (H5N1) wt. In order to determine the contribution of the internal protein genes of the
AA ca virus to protection, an additional group of ferrets was immunized with H1N1 A/New Caledonia/99 ca and challenged with H5N1 1997 wt. These
ferrets were not challenged with H5N1 2004 wt or A/Indonesia/05/2005 (H5N1) wt.
Lungs, nasal turbinates, and brains were harvested 3 d after challenge and were homogenized and titered on MDCK cells. Three ferrets per group were
evaluated. The lower limit of detection is indicated by the dashed line. *p , 0.05 compared to mock-immunized ferrets.
DOI: 10.1371/journal.pmed.0030360.g005
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strategy [5,6].
All humans are immunologically naı ¨ve with respect to the
HA at the start of a pandemic, and newly emerged
pandemic viruses contain at least an antigenically novel
HA and may also contain a novel NA subtype. Live,
attenuated inﬂuenza virus vaccines potentially offer three
major advantages over inactivated vaccines for rapid
immunization of an immunologically naı ¨ve population
[43]. First, in naı ¨ve populations, live virus vaccines induce
higher levels of antibody than inactivated virus vaccines
[21,44]. Second, live virus vaccines may induce protective
immunity more quickly and would require fewer doses than
inactivated vaccine [19]. In immunologically naı ¨ve popula-
tions, two doses of inactivated virus vaccine delivered 1 mo
apart are required for induction of immunity [45], and
signiﬁcant immunity is not achieved until the response to
the second dose is established, which occurs at about 40 d
after immunization. Even at this time, mucosal immunity,
especially that in the upper respiratory tract, is weak. In
contrast, live inﬂuenza virus vaccines against human
inﬂuenza viruses can induce a high level of immunity
following a single dose, and immunity is achieved as early
as 7–10 d following initial immunization, as indicated by
the clearance of the vaccine virus from the respiratory
tract. A live inﬂuenza virus vaccine induces both CD8
þ T
cell [46] and mucosal IgA antibodies in addition to serum
antibodies [42], and therefore is the vaccine of choice for
an immunologically naı ¨ve population. Third, the combined
humoral and mucosal immune response generated by live
virus vaccines in naı ¨ve populations results in broad
protection against antigenically drifted strains. For exam-
ple, the live, attenuated H3N2 human inﬂuenza vaccine
containing an A/Wuhan/359/95( H 3 N 2 ) - l i k es t r a i nw a s
effective in protecting against the A/Sydney/5/97 (H3N2)-
like antigenic drift variant [47]. This may be a particularly
useful feature in the event of a pandemic, in which a
vaccine generated from the emergent pandemic virus strain
is not available. Whether these theoretical advantages will
be seen with live, attenuated H5N1 vaccines in humans
remains to be established.
In summary, the modiﬁed H5N1 ca candidate vaccine
viruses were immunogenic in mice, attenuated in mice,
ferrets, and chickens, and protective in mice and ferrets
against subsequent challenge with homologous and heter-
ologous wt H5N1 inﬂuenza viruses. It is not known whether
investigational live virus vaccines bearing avian inﬂuenza
HA and NA genes in the AA ca background will be
overattenuated in humans or will be associated with some
residual virulence. Live, attenuated vaccines must be able to
replicate to levels that elicit a protective immune response
without causing disease in the host, so a balance between
attenuation and immunogenicity must be achieved. A live,
attenuated H5N1 vaccine would be administered to the
general population only if an inﬂuenza pandemic caused by
a virus of the H5N1 subtype were imminent, with
conﬁrmation of human-to-human transmission, or was
already underway in the United States, and it would be
used only on the recommendation of public health
authorities. However, it is important to generate and
carefully evaluate candidate live, attenuated H5N1 vaccines
in clinical trials in humans because of their potential
advantages over other vaccine approaches.
Supporting Information
Table S1. Assessment of Pathogenicity and Infectivity of H5N1 ca
Viruses in Chickens
Found at DOI: 10.1371/journal.pmed.0030360.st001 (38 KB DOC).
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Background. Influenza A viruses are classified into subtypes according
to two of the proteins from the virus surface, the hemagglutinin (HA) and
neuraminidase (NA) proteins, each of which occurs naturally in several
different versions. For example, the global epidemic (pandemic) of 1918–
1919 was caused by an influenza virus containing subtype 1
hemagglutinin and subtype 1 neuraminidase (H1N1), the 1957–1958
pandemic involved an H2N2 virus, and the 1969 pandemic, H3N2. Since
1997, several serious outbreaks of H5N1 infection have occurred in
poultry and in humans, raising concerns that H5N1 ‘‘bird flu’’ may cause
the next human influenza pandemic. Although human-to-human trans-
mission of H5N1 viruses appears limited, mortality rates in human
outbreaks of the disease have been alarmingly high—approximately
50%. A protective vaccine against H5N1 influenza might not only benefit
regions where transmission from poultry to humans occurs, but could
conceivably avert global catastrophe in the event that H5N1 evolves
such that human-to-human spread becomes more frequent.
Why Was This Study Done? Several approaches are in progress to
develop vaccines against H5N1 viruses. To date, the products that have
been tested in humans have not been very effective in producing a
strong immune response. To be optimal for human use, a vaccine would
have to be very safe, remain stable in storage, and provide protection
against influenza caused by naturally occurring H5N1 viruses that are not
precisely identical to the ones used to make the vaccine. This study was
done to develop a new H5N1 vaccine and to test it in animals.
What Did the Researchers Do and Find? The researchers developed
vaccines using three artificially constructed, weakened forms of the H5N1
influenza virus. The three vaccine viruses were constructed using flu virus
proteins other than HA and NA from an artificially weakened
(attenuated) strain of influenza. These were combined in laboratory-
grown cells with HA and NA proteins from H5N1 viruses isolated from
human cases during three different years: 2004, 2003, and 1997. They
grew larger quantities of the resulting viruses in hen’s eggs, and tested
the vaccines in chickens, ferrets, and mice.
In tests of safety, the study found that, unlike the natural viruses
from which they were derived, the vaccine strains did not cause death
when injected into the bloodstream of chickens, and did not even cause
infection when given through the birds’ breathing passages. Similarly,
while the natural viruses were lethal in mice at various doses, the vaccine
strains did not cause death even at the highest dose. In ferrets, infection
with the vaccine strains was limited to the upper respiratory tract, while
the natural viruses spread to the lungs and other organs.
In tests of protection, all mice that had received any of the three
vaccines survived following infection with any of the natural viruses (so-
called viral challenge), while unvaccinated mice died following viral
challenge. This occurred even though standard blood tests could not
detect a strong immune responses following a single dose of vaccine.
Challenge virus was detected in the lungs of the immunized mice, but at
lower levels than in the unvaccinated mice. Mice given two doses of a
vaccine showed stronger immunity on blood tests, and almost complete
protection from respiratory infection following challenge. In addition,
mice and ferrets that had received two doses of vaccine were protected
against challenge with H5N1 strains from more recent outbreaks in Asia
that differed substantially from the strains that were used for the vaccine.
What Do These Findings Mean? This study shows that it is possible to
create a live, attenuated vaccine based on a single H5N1 virus that can
provide protection (in mice and ferrets, at least) against different H5N1
viruses that emerge years later. Attenuated influenza virus vaccines of
this sort are unlikely to be useful to protect fowl because they do not
infect or induce an immune response in chickens. However, while the
safety and protection found in small animals are encouraging, it is not
possible to know without human testing whether a vaccine that protects
mice and ferrets will work in humans, or how this type of vaccine may
compare with others being developed for use in humans against H5N1
influenza. Tests of one of the vaccines in human volunteers in carefully
conducted clinical trials are currently under way.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030360.
  WHO Influenza Pandemic Preparedness page
  US Department of Health and Human Services Avian and Pandemic flu
information site
  Wikipedia entry on H5N1 (note: Wikipedia is a free Internet
encyclopedia that anyone can edit)
  CDC Avian Influenza Web page
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